| First Author | Ising C | Year | 2019 |
| Journal | Nature | Volume | 575 |
| Issue | 7784 | Pages | 669-673 |
| PubMed ID | 31748742 | Mgi Jnum | J:287425 |
| Mgi Id | MGI:6407568 | Doi | 10.1038/s41586-019-1769-z |
| Citation | Ising C, et al. (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575(7784):669-673 |
| abstractText | Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline(1). The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1beta release(2). Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice(3), the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation. |
